GLOMERULONEPHRITIS, IGA
Clinical trials for GLOMERULONEPHRITIS, IGA explained in plain language.
Never miss a new study
Get alerted when new GLOMERULONEPHRITIS, IGA trials appear
Sign up with your email to follow new studies for GLOMERULONEPHRITIS, IGA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug zigakibart tested for Long-Term kidney protection
Disease control Recruiting nowThis study looks at the long-term safety of a drug called zigakibart for people with IgA nephropathy, a kidney disease. It is for adults who have already finished another zigakibart study. Researchers will monitor side effects and check kidney function over 96 weeks.
Matched conditions: GLOMERULONEPHRITIS, IGA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:58 UTC
-
New drug iptacopan tested to see if it repairs kidney damage in rare disease
Knowledge-focused Recruiting nowThis study looks at how iptacopan affects the kidneys of 20 adults with IgA nephropathy, a kidney disease. Researchers will measure changes in kidney tissue and function over 9 months. The goal is to understand if the drug reduces immune system activity in the kidneys.
Matched conditions: GLOMERULONEPHRITIS, IGA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated May 26, 2026 03:53 UTC